Denali Therapeutics Inc (DNLI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
12-2023 | 12-2022 | 12-2021 | 12-2020 | 12-2019 | |
Cash Flows From Operating Activities | |||||
Net Income | -145,224 | -325,991 | -290,581 | 71,136 | -197,614 |
Depreciation Amortization | -27,226 | 8,746 | 17,341 | 8,586 | 2,972 |
Accounts payable and accrued liabilities | 2,431 | 2,274 | 3,705 | -1,623 | 1,033 |
Other Working Capital | -289,926 | -24,030 | -20,412 | 288,401 | 2,922 |
Other Operating Activity | 101,954 | 94,285 | 78,558 | 49,652 | 39,111 |
Operating Cash Flow | $-357,991 | $-244,716 | $-211,389 | $416,152 | $-151,576 |
Cash Flows From Investing Activities | |||||
PPE Investments | -12,939 | -17,833 | -8,500 | -3,095 | -17,919 |
Purchase Of Investment | -1,813,700 | -1,115,040 | -1,422,938 | -1,285,468 | -369,696 |
Sale Of Investment | 2,075,947 | 991,486 | 1,409,812 | 665,357 | 535,327 |
Investing Cash Flow | $249,308 | $-141,387 | $-21,626 | $-623,206 | $147,712 |
Cash Flows From Financing Activities | |||||
Common Stock Issued | 17,820 | 14,455 | 19,348 | 440,801 | 6,190 |
Other Financing Activity | 0 | 296,215 | 0 | 193,948 | 0 |
Financing Cash Flow | $17,820 | $310,670 | $19,348 | $634,749 | $6,190 |
Beginning Cash Position | 219,544 | 294,977 | 508,644 | 80,949 | 78,623 |
End Cash Position | 128,681 | 219,544 | 294,977 | 508,644 | 80,949 |
Net Cash Flow | $-90,863 | $-75,433 | $-213,667 | $427,695 | $2,326 |
Free Cash Flow | |||||
Operating Cash Flow | -357,991 | -244,716 | -211,389 | 416,152 | -151,576 |
Capital Expenditure | -12,939 | -17,833 | -8,500 | -3,095 | -17,919 |
Free Cash Flow | -370,930 | -262,549 | -219,889 | 413,057 | -169,495 |